Allam Fakhoury

Senior Scientific Director Medical Strategies and Evidence Generation Therapeutic Area Lead Epco @AbbVie

Provide scientific and technical support for assets in Hematology/Oncology. Deliver scientific presentations; develop and maintains professional and credible relationships with key opinion leaders. Actively participate in relevant Brand Teams and help develop medical affairs. Previously led a team of Medical/Scientific Strategy Directors in support of Venetoclax, Lemzoparlimab, ABBV-383 and Navitoclax. Currently (March 2022) USMA Team Leader for Epcoritamab (DuoBody®-CD3xCD20)- a proprietary bispecific antibody created using Genmab’s DuoBody® technology, jointly owned by Genmab and AbbVie Inc. It targets CD20 on the B-cells, a clinically well-validated target that is expressed in a wide variety of B-cell malignancies.